Stem Cell Heart Patches Improve Pumping in Small Study, Thickening Weakened Heart Walls
Updated
Updated · STAT · May 27
Stem Cell Heart Patches Improve Pumping in Small Study, Thickening Weakened Heart Walls
4 articles · Updated · STAT · May 27
A small study found engineered heart-muscle patches thickened damaged ventricular walls after implantation, boosting the heart’s pumping ability and modestly improving patients’ quality of life.
The patches are made from induced pluripotent stem cells and aim to re-muscularize tissue that the heart cannot naturally regenerate after a heart attack or other cardiovascular injury.
BioVAT — short for biological ventricular assist tissue — is being developed as a bridge for patients with end-stage heart failure who otherwise may need a transplant or a left ventricular assist device.
A larger trial is still needed to show how durable the benefit is and which patients are most likely to gain from the approach.
These heart patches seem miraculous, but what are the hidden long-term risks for patients?
When will stem cell patches be a real option for heart patients, not just a trial?
If we can now patch damaged hearts, could this make organ transplant lists a thing of the past?
Japan’s Conditional Approval of iPSC-Derived Heart Patches: A Global Turning Point in Regenerative Heart Failure Therapy
Overview
Japan has reached a historic milestone in regenerative medicine by granting conditional approval to ReHeart, an iPSC-derived heart patch therapy, through its unique Conditional and Time-Limited Approval pathway. This positions ReHeart as one of the world’s first iPSC-derived drugs and highlights Japan’s leadership in accelerating access to advanced therapies for patients with severe heart failure. The development of ReHeart and similar products relies on third-party iPS cells sourced from the CiRA Foundation at Kyoto University, showcasing a strong collaboration between academia and industry to advance medical science and address urgent patient needs.